Tag : CRSwNP

CONFERENCE UPDATE

Tezepelumab’s impact on activity levels in patients with severe, uncontrolled asthma and CRSwNP: Post-hoc analysis of the phase 3 NAVIGATOR study
Severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) can significantly limit patients' activity levels. This post hoc analysis of the phase 3 NAVIGATOR study assessed the impact of tezepelumab on activity-related items within the Asthma Quality of Life Questionnaire
CONFERENCE UPDATE

Symptom reduction and QoL improvement in CRSwNP patients with mepolizumab: Results from the phase 3 SYNAPSE trial
Chronic rhinosinusitis with nasal polyp (CRSwNP) is a chronic disease characterized by elevated interleukin 5 (IL-5) levels and is often associated with severe sinonasal symptoms and nasal obstruction. Mepolizumab is a humanized anti-IL-5 antibody approved as an add-on medication for CRSwNP. In the pivotal phase 3 SYNAPSE study, mepolizumab demonstrated improvement in sinonasal outcomes and reduction in corticosteroid use or surgery need in patients with CRSwNP. However, its effect on the number of low-symptom/symptom-free or symptom-reduced days remained unclear.